NSF has released an updated version of the NSF Grants.gov Application Guide (NSF 24-006). In general, the Guide has been revised to match the changes in NSF's Proposal and Award Policies and Procedures Guide (PAPPG) (NSF 24-1). A summary of changes by chapter is provided at the beginning of the document. 

The guide will be effective for applications submitted (via Grants.gov) or due on or after May 20, 2024. The guidelines in grantsgovguide0123 are applicable to proposals submitted before May 20, 2024.

Considering a career in research or wondering how to move forward in your quest to become an independent researcher? There are NIH funding programs for everyone, whether you're an undergraduate or graduate student, a postdoc, early stage or established investigator! To gain insight into the different programs by career stage, learn valuable tips, and comprehend the lingo of NIH funding, explore the NIH Funding Programs by Career Stage page.

The NIH institutional training grant application is currently being updated and will take effect for submissions due on or after January 25, 2025. If you are curious about the implications for your application preparation, consider participating in this live, virtual event on June 5, 2024.

The event will consist of NIH experts providing insights and updates on these changes, followed by a live Q&A session. Registration is mandatory, so make sure to reserve your spot today!

To learn more about the goals behind these changes, please visit the Updates to Training Grant Applications page. If you have any queries about this event, feel free to contact NIHGrantsEvents@nih.gov via email.

Undergraduate, predoctoral, and postdoctoral trainees and fellows receiving Kirschstein-NRSA awards in fiscal year 2024 will be compensated using stipend levels set by this notice that replaces NOT-23-076, which reflects the Further Consolidated Appropriations Act, 2024 (Public Law 118-047), signed into law on March 23, 2024.

The extramural research community is being informed about planned changes to the Research Performance Progress Report (RPPR) instructions to address the NIH Data Management and Sharing Policy. Once OIRA approves, the NIH RPPR Instruction Guide will be posted on the Research Performance Progress Report (RPPR) page. NIH is going to implement the new questions for RPPRs submitted on or after October 1, 2024.NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Reporting Data Management and Sharing (DMS) Plan Activities in the Research Performance Progress Report (RPPR) NOT-OD-24-123. NIH

This notice provides the research and research training community with an overview of application and peer review changes impacting grant applications submitted for due dates on or after January 25, 2025, including:

•    Simplified Review Framework for Most Research Project Grant Applications
•    Revisions to the NIH Fellowship Application and Review Process
•    Updates to Reference Letter Guidance
•    Updates to NRSA Training Grant Applications
•    Updated Application Forms (FORMS-I)
•    Common Forms for Biographical Sketch and Current and Pending (Other) Support

NIH will provide more information and guidance on these initiatives throughout 2024, which will be referred to in this notice as well.

The purpose of this notice is to provide updates and plans for implementing the simplified peer review framework for most research project grant applications announced in October (NOT-OD-24-010). It updates and clarifies the activity codes impacted, the plans to update funding opportunities, and the timing of when application forms will be available.

NIH is on schedule to implement the simplified review framework for applications that have due dates on or after January 25, 2025.

The applicant and recipient communities are notified of changes to grant application forms and application guide instructions for due dates on or after January 25, 2025 through this notice.

The application forms below have substantial modifications (i.e., new/deleted/modified fields). All other forms are limited to an OMB expiration date change.

•    PHS 398 Research Training Program Plan
•    PHS Fellowship Supplemental Form
•    PHS Assignment Request Form
•    PHS 398 Cover Page Supplement Form

This notice informs about the modifications made to the application and peer review process for NIH and AHRQ fellowship applications beginning with submissions that are due after January 25, 2025. The overall goal of the changes is to facilitate the mission of fellowship peer review - to identify the most promising candidates and provide individualized training opportunities that will assist them along their path to support the advancement of the biomedical research enterprise.

My bibliography contains information on eRA Commons users who have received grants in their portfolio. They are able to determine whether their publications comply with the NIH Public Access Policy, initiate the compliance process and link their publications to NIH extramural awards. The steps to manage compliance with the NIH public access policy can be found here.

A. Pre-announcements released:

1.The Alcohol and Substance Use Disorders Research Program (ASUDRP) released a pre-announcement for the following funding opportunities:

·        Consortium Award

To view the pre-announcement, click here.

2.The Lupus Research Program (LRP) released a pre-announcement for the following funding opportunities:

·        Idea Award

·        Impact Award

·        Transformative Vision Development Award

·        Transformative Vision Award

To view the pre-announcement, click here.

3.The Parkinson’s Research Program (PRP) released a pre-announcement for the following funding opportunities:

·        Early Investigator Research Award

·        Investigator-Initiated Research Award

To view the pre-announcement, click here.

B. Funding announcements released:

1.The Rare Cancers Research Program (RCRP) released the following funding opportunities:

·        Concept Award

·        Idea Development Award

·        Resource and Community Development Award

To view the funding opportunity announcement and submit a pre-application, click here. 

2.The Multiple Sclerosis Research Program (MSRP) released the following funding opportunities:

·        Clinical Trial Award

·        Early Investigator Research Award

·        Exploration – Hypothesis Development Award

·        Investigator- Initiated Research Award

To view the funding opportunity announcement and submit a pre-application, click here.

3.The Tick-Borne Disease Research Program (TBDRP) released the following funding opportunities:

·        Idea Development Award

·        Therapeutic/Diagnostic Research Award

To view the funding opportunity announcement and submit a pre-application, click here.

4.The Tuberous Sclerosis Complex Research Program (TSCRP) released the following funding opportunities:

·        Clinical Translational Research Award

·        Exploration – Hypothesis Development Award

·        Idea Development Award

To view the funding opportunity announcement and submit a pre-application, click here.

5.The Autism Research Program (ARP) released program announcement for the following funding opportunity:

·        Discovery Award

To view the funding opportunity announcement and submit a pre-application, click here.

6.The Pancreatic Cancer Research Program (PCARP) released program announcements for the following funding opportunities:

·        Focused Pilot Award

·        Idea Development Award

·        Translational Research Partnership Award

To view the funding opportunity announcement and submit a pre-application, click here.

7.The Prostate Cancer Research Program (PCRP) released program announcements for the following funding opportunities:

•        Data Science Award

•        Early Investigator Research Award

•        Exploration-Hypothesis Development Award

•        Idea Development Award

•        Physician Research Award

To view the funding opportunity announcement and submit a pre-application, click here.

8.The Duchenne Muscular Dystrophy Research Program (DMDRP) released program announcements for the following funding opportunities:

·        Idea Development Award

·        Clinical/Translational Research Award

To view the program announcements and submit a pre-application, click here.

9.The Melanoma Research Program (MRP) released program announcements for the following funding opportunities:

·        Survivorship Research Award *NEW for FY24*

·        Idea Award

·        Melanoma Academy Scholar Award

·        Team Science Award

·        Focused Program Award – Rare Melanomas

To view the program announcements and submit a pre-application, click here.

10.The Peer Reviewed Orthopaedic Research Program (PRORP) released program announcements for the following funding opportunity:

·        Women’s Health Research Award *NEW for FY24*

·        Applied Research Award

·        Clinical Translational Research Award

·        Clinical Trial Award

To view the program announcements and submit a pre-application, click here.

11.The Prostate Cancer Research Program (PCRP) released a program announcement for the following funding opportunity:

·        Implementation Science Award

To view the program announcements and submit a pre-application, click here.

12.Lung Cancer Research Program

i) Pre-Application (Preproposal) submission deadline is May 28, 2024 5:00 p.m. Eastern Time for the following FY24 LCRP funding opportunities:

o   Idea Development Award

o   Translational Research Award

ii) Pre-Application (Letter of Intent) submission deadline is May 28, 2024 5:00 p.m. Eastern Time for the following FY24 LCRP funding opportunities:

o   Concept Award

o   Career Development Award

To view the funding opportunity announcements and submit a pre-application, click here.

Due: May 27, 2024

• Amount: $250,000/1 year

• Notes: The foundation is seeking projects focused on tumors of the upper GI tract. Proposals should aim to drive disruptive research, with the goal of advancing the field of gastric and esophageal cancer research and ultimately improving patient outcomes. Proposals should cover topics such as understanding the molecular mechanisms underlying tumor initiation and progression, resistance, and metastasis; identifying novel biomarkers for early detection; and developing innovative treatment strategies including identifying and characterizing novel targets. PIs must be independent researchers at their respective institutions. Proposals from investigators at all career stages, especially those new to the field of upper GI cancers, are welcome. To facilitate this, preclinical resources (cell lines, organoids, and mouse models) will be made available to researchers who request them. Interdisciplinary collaborations are encouraged. Researchers are limited to one application as PI but may be co-investigators on other proposals without limitations.

• Link: ASPIRE Award

Due: June 3, 2024 (LOI)

Amount: $600,000 over 2 years

• Notes: Program is dedicated to advancing academic discoveries into medicines for Alzheimer’s disease and related dementias. This unique award provides funding and project support by a team of pharmaceutical industry experts through a collaboration with the Alzheimer’s Drug Discovery Foundation (ADDF) and the Brain Health Medicines Centers of the Harrington Discovery Institute.

Lead investigator must have an MD, a PhD, or equivalent. Proposals should show potential to advance discovery into meaningful therapeutics to treat, prevent, slow, or reverse Alzheimer’s disease or related dementias (vascular dementia, frontotemporal dementia, Lewy Body dementia, LATE etc).

Team should possess intellectual property (IP) or have potential for novel IP that has not yet been licensed to a for-profit entity. Researchers working on drug development programs that are relevant to but not presently focused on the Alzheimer’s field are strongly encouraged to apply. Therapeutic targets with a clear marker of target engagement, either established or in development will be considered of high priority.

The ADDF-Harrington Scholar Program does not support target discovery, assay development, or high throughput screening campaigns.



• Link: ADDF-Harrington Scholar Program | Alzheimer's Drug Discovery Foundation

(alzdiscovery.org)

The Office of Development and Alumni Relations along with the Office of Grant Support and the Einstein Awards Committee is excited to announce the W.M. Keck Foundation’s Research funding opportunity. Grants of ~$1 million will be offered for a maximum period of three years. Senior, mid-career or early-stage faculty (tenure-track assistant professors or above) can apply. 

The mandate of the W.M. Keck Foundation’s Research Program is to support pioneering discoveries in Medical Research and Science & Engineering. The Foundation funds high-risk and high-impact work to lay the groundwork for new paradigms, technologies, and discoveries that will save lives, provide innovative solutions, and add to our understanding of the world. They are seeking paradigm-shifting proposals dealing with basic science, and ideas that have “potential to break open new territory in their field.” Future clinical applications are seen as a plus, but translational research is not their focus.



The W.M. Keck Foundation funds fundamental science projects in two specific areas: 1) Medical Research and 2) Science and Engineering (S&E). 

Foundation will fund scientific research which is: 

• A breakthrough / scientific leap forward (in this project) 
• Project can be hypothesis-driven, but it does not have to be 
• High impact / possibly high risk 
• The project team has the necessary expertise 
• Project-driven instrumentation can be included 
• Have potential to develop breakthrough technologies, instrumentation, or methodologies
• Demonstrate a high love of risk due to unconventional approaches or challenge the prevailing paradigm
• Have potential for transformative impact such as the founding of a new field of research, enabling of new observations, or altering perception of a previously intractable problem
• Project falls outside the mission of public funding agencies (e.g., NIH, NSF, DoD, etc.). 

• Applicants need to demonstrate why private philanthropy generally, and the Keck Foundation in particular, is essential to the project’s success. The foundation wants applicants to insert direct quotes received from public funding agencies' feedback as to why their project did not get funded (e.g., “high-quality but too risky”).  

The foundation will not fund the following: 

• Drug development and delivery/biomarker identification 
• Treatment trials or research for the sole purpose of drug development
• Medical devices and translational research
• Clinical research / therapies 
• Translational research
• Extension of current work/next logical step — even if significant 
• Projects that are too narrow/too specific, including disease-specific
• User facilities 
• Application, efficiency/optimization, or cost cannot be the main drivers 
• No supplements or renewals  

The deadline for submission of concept papers for internal review by the Einstein Awards Committee is Friday, June 7, 2024 by 5:00 PM. Please email your single-paged concept paper as a PDF following the outline given below to: indranil.basu@einsteinmed.edu by June 7 at 5:00 PM.  

Single-paged concept papers must be in 12 point font with 1 inch margins and include: 

• Organization Name 
• Project Title 
• Full name of Principal Investigator 
• An overview of the proposed project emphasizing any unique aspects and pilot studies (indicate area of emphasis for project – Medical Research or Science & Engineering Research) 
• A description of the methodologies and key personnel 
• A brief justification of the need for Keck Foundation support Applicants need to demonstrate why private philanthropy generally, and the Keck Foundation in particular, is essential to the project’s success. The foundation wants applicants to insert direct quotes received from public funding agencies feedback as to why their project did not get funded (e.g., “high-quality but too risky”). 
• An estimated budget broken down, if possible, by major areas, e.g. personnel, equipment, consumable supplies, etc. 
• With any remaining space within the 1 page limit, authors may add other details 
• If a reference is necessary, abbreviate it as (Science, 323, 45, ‘11). DO NOT USE (Jones et al., 2011). Please avoid any illustrations.   

Please find details of Keck Foundation Grant Program Eligibility and Priorities. Please visit the Foundation's Grant Abstracts Webpage to view the types of research projects and award amounts recently funded by the Keck Foundation. From among these applications, the Einstein awards committee select up to four candidates in each of the two categories (Medical Research and S&E), for a total of up to eight concept candidates. Einstein’s institutional liaison officer will then submit the nominated concept papers to the Foundation for a preliminary review on July 2, 2024. Following this review, one selected applicant in each category will be invited to submit a Phase I application by November 1, 2024. Faculty members who have previously submitted a concept paper to the Einstein awards committee but were not selected to move ahead based on feedback received from the foundation, are most welcome to submit a concept paper. 

If you have any questions, please contact amcinerney@montefiore.org (Institutional Liaison Officer). 

A. Postdoctoral Fellowships

• Due: June 7, 2024 (LOI)

• Amount: $200k/2 years

The purpose of this fellowship is to encourage specialization in spinal cord injury

research. The Fellow should be mentored by an investigator(s) experienced in SCI research. Key criteria for Fellowships include qualifications of the Fellow, how the training plan and environment provided by the mentor(s) will enhance the Fellow’s research career, scientific merit of the proposal, and relevance of the project to the foundation’s portfolio.

• Grants will be awarded for novel approaches to improving function and develop curative

therapies after SCI. Areas include:

1) Mechanistic research aimed at neuroprotection and/or elucidation of the pathological mechanisms that occur after SCI; promotion of neuronal survival, axonal regeneration, synaptogenesis, myelination, and functional connectivity after SCI; development of therapeutics to improve function after SCI, including cellular, pharmacologic, or bioengineering strategies; and chronic SCI treatment and issues related to aging with SCI. 2) Preclinical, translational research aimed at enabling future clinical trials, such as the effects of SCI and novel interventions on sensory and motor function; use of preclinical models of SCI to develop interventions to alleviate complications of SCI including bowel, bladder, sexual, and other autonomic dysfunctions, respiratory dysfunction, neuropathic pain, pressure sores, osteoporosis, and the effects of aging with SCI; and trial-enabling studies, e.g., to confirm the mechanism of action for novel therapeutics, dosing, toxicity.

3) Clinical research aimed at establishing the natural history and progression of functional outcomes over time after SCI; efforts to develop and validate outcome measures needed to facilitate definitive clinical trials in SCI populations; and testing of innovative rehabilitation strategies and devices in persons with SCI.

Funding may be sought to allow applicant to obtain data to establish a line of research if the proposal provides strong rationale.

• Eligibility: MD, DVM, or PhD. US citizenship is not required. Fellows must have their doctoral degree or equivalent by the LOI submission and have held that degree no longer than five years before the full grant submission on 11/8. For MDs, the five-year eligibility period begins after completion of the residency program.

• Link: SCRITS RFP

B. Pilot Research Grants

• Due: June 7, 2024 (LOI)

• Amount: $400k/2 years

This funding is intended to support pilot studies that lay essential groundwork, allow

either junior or established PIs to test the feasibility of novel methods and procedures and/or collect new data that can lead to or enhance larger-scale studies. Grants will be awarded for novel approaches to improving function and develop curative therapies after SCI. Areas include:

1) Mechanistic research aimed at neuroprotection and/or elucidation of the pathological

mechanisms that occur after SCI; promotion of neuronal survival, axonal regeneration,

synaptogenesis, myelination, and functional connectivity after SCI; development of therapeutics to improve function after SCI, including cellular, pharmacologic, or bioengineering strategies; and chronic SCI treatment and issues related to aging with SCI. 2) Preclinical, translational research aimed at enabling future clinical trials, such as the effects of SCI and novel interventions on sensory and motor function; use of preclinical models of SCI to develop interventions to alleviate complications of SCI including bowel, bladder, sexual, and other autonomic dysfunctions, respiratory dysfunction, neuropathic pain, pressure sores, osteoporosis, and the effects of aging with SCI; and trial-enabling studies, e.g., to confirm the mechanism of action for novel therapeutics, dosing, toxicity.

3) Clinical research aimed at establishing the natural history and progression of functional outcomes over time after SCI; efforts to develop and validate outcome measures needed to facilitate definitive clinical trials in SCI populations; and testing of innovative rehabilitation strategies and devices in persons with SCI. Funding may be sought to allow applicant to obtain data to establish a line of research if the proposal provides strong rationale.

• Eligibility: MD, DVM, or PhD. US citizenship is not required. Applicants must have degree beyond the postdoc level (e.g., Instructor, Assistant Professor+) and demonstrate appropriate experience to serve as an independent PI. Those who don’t hold a tenure track position may include a Letter of Assurance from Dean or Dept. Chair confirming their independent position and availability of space and equipment. PIs can be from a range of disciplines, but relevant SCI experience must be represented on the proposed research team. Junior investigators project need not be high risk. Established investigators should demonstrate a change in direction of previous work, where the elevated risk of failure is balanced by high potential impact.

• Link: SCRITS RFP

C. Senior Research Grants

• Due: June 7, 2024 (LOI)

• Amount: $800k/3 years

This funding is intended to encourage pursuit of new avenues, enable paradigm shifts, or

support decisive translational steps in developing SCI treatments. Applicants should propose transformative projects that explore new areas of SCI research or fill important gaps in the field. The goal is not to substitute for federal funding, but to use Neilsen Foundation funds to foster cutting-edge ideas and approaches that have great potential, despite inherent risk. Grants will be awarded for novel approaches to improving function and develop curative therapies after SCI. Areas include:

1) Mechanistic research aimed at neuroprotection and/or elucidation of the pathological mechanisms that occur after SCI; promotion of neuronal survival, axonal regeneration, synaptogenesis, myelination, and functional connectivity after SCI; development of therapeutics to improve function after SCI, including cellular, pharmacologic, or bioengineering strategies; and chronic SCI treatment and issues related to aging with SCI. 2) Preclinical, translational research aimed at enabling future clinical trials, such as the effects of SCI and novel interventions on sensory and motor function; use of preclinical models of SCI to develop interventions to alleviate complications of SCI including bowel, bladder, sexual, and other autonomic dysfunctions, respiratory dysfunction, neuropathic pain, pressure sores, osteoporosis, and the effects of aging with SCI; and trial-enabling studies, e.g., to confirm the mechanism of action for novel therapeutics, dosing, toxicity.

3) Clinical research aimed at establishing the natural history and progression of functional outcomes over time after SCI; efforts to develop and validate outcome measures needed to facilitate definitive clinical trials in SCI populations; and testing of innovative rehabilitation strategies and devices in persons with SCI. Funding may be sought to allow applicant to obtain data to establish a line of research if the proposal provides strong rationale.

• Eligibility: MD, DVM, or PhD. US citizenship is not required. Associate Professor or above. PIs can be from a range of disciplines, but relevant SCI experience must be represented on the proposed research team.

• Link: SCRITS RFP

If you have any questions, please contact amcinerney@montefiore.org.

• Due: June 9, 2024

• Amount: $150,000

Intended to support early-career investigators working to advance human immunology, vaccine discovery, and immunotherapy research for major global diseases. The committee “will be looking for research aimed at tackling the current roadblocks that exist in human vaccine development and expanding our limited understanding of key immune processes that are fundamental to successful vaccine and immunotherapy development.”

If you have any questions, please contact amcinerney@montefiore.org.

• Due: June 11, 2024

• Amount: $250,000 over 2 years

The purpose of this funding opportunity is to stimulate and accelerate discovery and

development of new, transformative therapies for epilepsy, moving promising, well-supported preclinical and/or clinical research closer to clinical application. The award is intended to support nimble development of data necessary to attract larger commercialization funding opportunities and is not intended to replace those opportunities. Projects based on novel biological pathways and/or highly differentiated therapeutic approaches which are likely to have a high probability of successfully transitioning to clinical development are strongly encouraged.

The award is not intended to fund basic research on the mechanisms underlying epilepsy.

Eligible PIs must be independent researchers at or above the level of Assistant Professor (or equivalent) at universities and non-academic research institutions; Postdocs are not eligible to apply.

If you have any questions, please contact amcinerney@montefiore.org. 

• Due: June 15, 2024 (nominations are due; applications are due July 1)

• Amount: $150,000

The Career Advancement Award assists outstanding early-career vision scientists in

pursuit of ongoing research of unusual significance and promise. Must have nomination from Department Chair. Chair may nominate one applicant in each award category. Awards are available in 3 categories:

1) The RPB / David Epstein Career Advancement Award in Glaucoma Research sponsored by Alcon* will focus on a research project in glaucoma.

2) The RPB / TGF* Career Advancement Award will focus on glaucoma research,

specifically on degeneration of human ganglion cells with openness to connectomic;

genetic; imaging; and epidemiologic approaches, as well as regeneration approaches for glaucoma research.

3) The RPB Career Advancement Award will not have a specific scientific focus and is open to any topic within vision research.

• Eligibility: available to candidates who have already received their first NIH R01 and are collecting new data to secure a second R01. Candidates must have their first NIH R01 with at least one year remaining by the application deadline. The award is open to any Assistant or Associate Professors (MDs, PhDs, or MD/PhDs) from any institution of higher education in the U.S.

If you have any questions, please contact amcinerney@montefiore.org.

Sponsored by the Josiah Macy Jr. Foundation, the Macy Faculty Scholars Program, a prestigious national award, is designed to develop and advance the careers of junior faculty medical educators. The Scholars Program annually competitively selects and funds FIVE scholars from across the nation. Albert Einstein College of Medicine may nominate ONE faculty member for consideration for the 2025 Program. Awards are intended to cover 50% protected time up to a cap of $100,000 per year for 2 years.

Eligibility criteria: 

·     Candidates must have been awarded a doctorate in medicine, biomedical sciences, or a related field. 

·     Nominees must be hold full-time appointments at the rank of assistant or associate professor or equivalent. Appointments such as research assistant professor, adjunct assistant professor, assistant professor research track, visiting professor, or instructor are NOT eligible. 

·     Candidates must NOT have been appointed as faculty at any institution prior to July 1, 2015, whether or not such appointment was on a tenure track. Time spent on clinical internships, residencies, on work towards board certification, or on parental leave does not count as part of this eight-year limit. 

SAVE THE DATE: An informational webinar for applicants will be held by the Josiah Macy Jr Foundation on Wednesday, May 29 at 1:00 pm ET. RSVP Today.

Application Materials

Note: The deadline for submission of preliminary applications for internal review by Einstein’s Education Awards Committee is 5 PM, June 26, 2023.

Please send ONE PDF file containing the following as an email attachment to susan.legnini@einsteinmed.edu.  



·     Candidate Profile Form (click here). 

·     A statement by the applicant on career objectives and personal goals for this program, limited to no more than TWO single-spaced pages.

·     A mentor’s statement outlining the applicant’s career potential, limited to no more than ONE single-spaced page.

·     A Departmental letter of support limited to no more than TWO single-spaced pages.  

·     A written proposal containing a title and a description of the proposed educational scholarship project to be carried out during the grant period, limited to no more than THREE single-spaced pages, plus one additional page (single-spaced) for references with titles included. The font should be 11-point or larger, and the margins should be at least 0.5 inches. Figure legends can use smaller fonts.  

·     A complete curriculum vitae and bibliography. Do NOT submit an NIH biosketch. 

·     Information about present and pending grant support with amounts requested or approved, annual amounts, and duration of award. 

Complete guidelines for this program can be accessed by clicking here.

If you have any questions concerning this award or the application procedure, please contact susan.legnini@einsteinmed.edu.

Due: July 8,2024 @ 4pm

Amount: $400,000/2 years

The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with “high-risk/high-reward” ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis, or treatment of cancer. The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. Applications will be accepted from all scientific disciplines provided that the proposed research meets the selection criteria.

Eligibility: The applicant must have received an MD, DO, PhD, or MD/PhD degree. Tenure-track Assistant Professors within the first five (5) years of obtaining their initial Assistant Professor position (Cut-off date: July 1, 2019). Clinical Instructors and Senior Clinical Fellows (in the final year of sub-specialty training) holding an MD, MD/PhD, DO who are pursuing a period of independent research before taking a tenure-track faculty position. Such individuals must have an exceptional record of research accomplishment, dedicated laboratory space and the support of their institution. Applicants with a background in multiple disciplines are especially encouraged to apply.



If you have any questions, please contact amcinerney@montefiore.org.

This two-year grant of $130,000 is a joint effort to encourage and support a postdoctoral or clinical research fellow.

To conduct endometrial cancer research and to establish a successful career path in this field. Projects may be basic, translational, clinical, or epidemiological in nature. There are no citizenship or geographic requirements.

The deadline to submit applications is July 18. 

Applicants must have a doctoral degree (including PhD, MD, MD/PhD, or equivalent) in a related field and not currently be a candidate for a further doctoral degree.

At the start of the grant term on November 1, 2024, applicants must:

i) Hold a mentored research position with the title of postdoctoral fellow, clinical research fellow, or the equivalent. Visit the website for eligibility details. 

ii) Have completed their most recent doctoral degree within the past five years (i.e., degree cannot have been conferred before November 1, 2019; the formal date of receipt of doctoral degree is the date the degree was conferred, as indicated on their diploma and/or transcript).

Click here for more details.

Empire State Development’s Division of Science, Technology, and Innovation (“NYSTAR”), Innovation Matching Grants Program (the “IMG Program”) aims to grow small businesses and support the development of new technologies in New York State by providing matching funds for federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants.

The New York State Innovation Matching Grants Program will match: 

The award for Phase I applicants, not to exceed $100,000. 

The award for Phase II applicants, not to exceed $200,000. 

and provide technical assistance resources for Phase II and Phase III awards. 

In no event, shall the funding provided from the IMG Program exceed 50% of the federal award. A funding commitment made through the IMG Program demonstrates New York State support to strengthen certain proposals, increase the likelihood that New York State businesses will be awarded competitive federal SBIR/STTR funding, and supports the growth of promising small businesses in New York. Click here for more details.